USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
13 Jun 2022 | 02:45 PM GMT

Combo DTx-drug: Pharma opportunities

Anchored by:

Smit Patel
Doctor of Pharmacy
THE OHIO STATE UNIVERSITY

Participants:

Smit Patel Doctor of PharmacyThe Ohio State University
Smit Patel
Doctor of PharmacyThe Ohio State University
Chandana Fitzgerald President, CommunityHLTH
Chandana Fitzgerald
President, CommunityHLTH
Anish Shindore Founder & Managing PartnerGSD Health
Anish Shindore
Founder & Managing PartnerGSD Health
Anna-Maria Heidinger Head of Digital Innovation HubDaiichi Sankyo Europe
Anna-Maria Heidinger
Head of Digital Innovation HubDaiichi Sankyo Europe
Brian Mahony Medical Research FellowBioinnovate
Brian Mahony
Medical Research FellowBioinnovate
Caoimhe Vallely-Gilroy Independent Advisor - Pharma & LifesciencesBasel Area, DayOne
Caoimhe Vallely-Gilroy
Independent Advisor - Pharma & LifesciencesBasel Area, DayOne
Chris Wasden Chief Strategy OfficerTwill
Chris Wasden
Chief Strategy OfficerTwill
Emily Lewis Global Digital Transformation LeadUCB
Emily Lewis
Global Digital Transformation LeadUCB
Jaydev Thakkar Chief Operations OfficerBiofourmis
Jaydev Thakkar
Chief Operations OfficerBiofourmis
Ricardo C. Berrios Co-Founder & CEOAdhera Health, Inc.
Ricardo C. Berrios
Co-Founder & CEOAdhera Health, Inc.
Simon Bock Market Access ManagerTiefenbacher Pharmaceuticals
Simon Bock
Market Access ManagerTiefenbacher Pharmaceuticals
Smit Patel AdvisorEconomist Impact
Smit Patel
AdvisorEconomist Impact
Tahir Hussain Global Pharma Business Dev. Digital HealthBiofourmis
Tahir Hussain
Global Pharma Business Dev. Digital HealthBiofourmis

About this Meeting

DTx-drug combinations (‘combo’) are becoming one of the easiest ways for digital therapeutics (DTx) companies to commercialize their products through pharma. Given that the pharma industry remains wary of incorporating standalone DTx in their portfolios, what are opportunities for pharma to leverage DTx as a companion for their drugs?  

This meeting will focus on DTx-drug combinations that act as enhancers of pharmacotherapy and examine how to successfully build and commercialize them as a combo. We will discuss: 

  • How can pharma leverage DTx to improve patients’ experience with their drugs? What is the return on investment (ROI) for pharma?  
  • When is the right moment to incorporate the DTx (co-development during trials, from phase III, when the drug is already on the market, or other)? Can drug-DTx combos ease the market access process of the drug?  
  • Beyond financial reasons, what are the main drivers for pharma to incorporate DTx solutions in the care plans of their drugs? 
  • What are the main factors when choosing the right companion for a specific drug? What are the therapeutic areas best suited to build these combos? 
  • What does the promotion of these combos look like?